The National Institute for Health and Care Excellence raises its cost-effectiveness threshold

What might this mean for the Pharmaceutical Industry?

1. Better odds of NHS reimbursement
Because the threshold is higher, more expensive drugs with meaningful but costly health benefits have a stronger chance of being deemed “cost-effective.” NICE itself estimates that the higher threshold could lead to 3–5 additional medicines or indications being recommended each year compared with the old range.

2. Pricing and strategy implications

• Pharma companies can price new medicines with slightly higher cost-effectiveness ratios and still meet NICE’s criteria.
• However, it does not automatically mean a blanket price increase for all products — companies still need to justify their prices based on clinical benefit and comparative value.
• The reduced VPAG rebate rate (to ~15 %) improves the commercial environment for branded drug sales in the UK, potentially increasing net returns and making the UK a more commercially viable market.

3. Investment and competitiveness

• Industry groups (e.g., ABPI) have long argued that the old threshold was out of date and hurt the UK’s attractiveness as a launch market compared with Europe and the US. The change is seen as a move to retain and attract R&D and commercial investment.

What might this mean for patients?

Improved access to some new treatments

Patients may gain faster access to innovations that previously fell just above the old cost-effectiveness cutoff, especially in therapeutic areas with high unmet need (e.g., certain cancers or rare diseases).

Broader access debates continue

• While the threshold increase helps with fielding more drug approvals, overall NHS budget constraints and how cost-effective thresholds interact with total spending remain contentious. Some critics warn that spending more on certain drugs without increasing overall funding could strain other parts of the health system.

In Summary…

The QALY threshold increase is one of the most significant updates to UK health technology assessment in decades. It’s intended to:

• Encourage pharma innovation and investment
• Make it easier for the NHS to approve certain new drugs
• Modernise cost-effectiveness assessment to better reflect current economic realities

For the pharmaceutical industry, this change improves the chance that higher-cost but beneficial medicines will be reimbursed in the UK. For patients, it potentially expands access to new therapies while keeping NHS funding decisions rooted in value, though the real-world effect will depend on NHS budgets and individual drug evaluations.